Lipella Pharmaceuticals Inc.
LIPO
$2.52
$0.031.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 536.40K | 483.50K | 507.20K | 477.50K | 449.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 536.40K | 483.50K | 507.20K | 477.50K | 449.60K |
| Cost of Revenue | 3.61M | 3.01M | 2.79M | 3.19M | 3.04M |
| Gross Profit | -3.08M | -2.52M | -2.28M | -2.71M | -2.59M |
| SG&A Expenses | 2.00M | 1.84M | 1.97M | 2.17M | 2.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.62M | 4.84M | 4.76M | 5.36M | 5.20M |
| Operating Income | -5.08M | -4.36M | -4.26M | -4.88M | -4.75M |
| Income Before Tax | -5.02M | -4.26M | -4.14M | -4.74M | -4.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.02 | -4.26 | -4.14 | -4.74 | -4.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.02M | -4.26M | -4.14M | -4.74M | -4.62M |
| EBIT | -5.08M | -4.36M | -4.26M | -4.88M | -4.75M |
| EBITDA | -5.08M | -4.36M | -4.25M | -3.30M | -2.09M |
| EPS Basic | -4.78 | -4.40 | -4.95 | -6.10 | -6.28 |
| Normalized Basic EPS | -2.99 | -2.75 | -3.09 | -3.82 | -3.93 |
| EPS Diluted | -4.78 | -4.40 | -4.95 | -6.13 | -6.34 |
| Normalized Diluted EPS | -2.99 | -2.75 | -3.09 | -3.82 | -3.93 |
| Average Basic Shares Outstanding | 4.19M | 3.83M | 3.43M | 3.20M | 3.00M |
| Average Diluted Shares Outstanding | 4.19M | 3.83M | 3.43M | 3.20M | 3.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |